CanSino Biologics Inc. (6185.HK)
HKD 30.9
(-0.16%)
HKD 30.9
(-0.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.31 Billion CNY | -18.75% |
| 2022 | 11.46 Billion CNY | -3.41% |
| 2021 | 11.87 Billion CNY | 75.96% |
| 2020 | 6.74 Billion CNY | 278.15% |
| 2019 | 1.78 Billion CNY | 124.22% |
| 2018 | 795.87 Million CNY | -8.14% |
| 2017 | 866.36 Million CNY | 165.61% |
| 2016 | 326.17 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 8.56 Billion CNY | -8.05% |
| 2024 Q2 | 8.13 Billion CNY | -5.07% |
| 2023 Q2 | 9.89 Billion CNY | -11.75% |
| 2023 FY | 9.31 Billion CNY | -18.75% |
| 2023 Q4 | 9.31 Billion CNY | -3.04% |
| 2023 Q3 | 9.61 Billion CNY | -2.9% |
| 2023 Q1 | 11.21 Billion CNY | -2.21% |
| 2022 Q2 | 11.98 Billion CNY | 0.46% |
| 2022 FY | 11.46 Billion CNY | -3.41% |
| 2022 Q4 | 11.46 Billion CNY | -0.61% |
| 2022 Q3 | 11.53 Billion CNY | -3.75% |
| 2022 Q1 | 11.93 Billion CNY | 0.5% |
| 2021 Q4 | 11.87 Billion CNY | 9.09% |
| 2021 Q1 | 7.52 Billion CNY | 11.49% |
| 2021 Q2 | 10.25 Billion CNY | 36.27% |
| 2021 Q3 | 10.88 Billion CNY | 6.18% |
| 2021 FY | 11.87 Billion CNY | 75.96% |
| 2020 Q4 | 6.74 Billion CNY | 1.29% |
| 2020 FY | 6.74 Billion CNY | 278.15% |
| 2020 Q2 | 1.71 Billion CNY | -1.46% |
| 2020 Q3 | 6.66 Billion CNY | 289.45% |
| 2020 Q1 | 1.73 Billion CNY | -2.72% |
| 2019 Q4 | 1.78 Billion CNY | 0.0% |
| 2019 FY | 1.78 Billion CNY | 124.22% |
| 2019 Q2 | 1.84 Billion CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 FY | 795.87 Million CNY | -8.14% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q3 | 795.87 Million CNY | 0.0% |
| 2018 Q4 | 795.87 Million CNY | 0.0% |
| 2017 FY | 866.36 Million CNY | 165.61% |
| 2016 FY | 326.17 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -926.901% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 58.611% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -623.963% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | -344.787% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -1849.056% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | -222.374% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | -229.569% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | -439.488% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -1004.168% |
| SSY Group Limited | 11.96 Billion HKD | 22.125% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | -571.044% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | -167.254% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 96.57% |